Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for Prevention of Recurrent Atrial Fibrillation in Heart Failure
NCT01887353Phase 2Terminated
- Sponsor
- Intermountain Health
- Start
- Jun 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Ranolazine with Placebo (2 arms). Primary endpoint: Time to First Atrial Fibrillation Recurrence at 6 months. Started Jun 2013; status: terminated.
02
Drugs
ranolazine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01887353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01887353.